ORCID as entered in ROS
https://orcid.org/0000-0002-7380-1170
Select Publications
Conference Papers
, 2014, 'POLO-LIKE KINASE 1 AS A BIOMARKER IN RECTAL CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in study COU-AA-302for metastatic castration-resistant prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, pp. 13 - 13, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Reducing invasion potential of cervical cancer cells via targeted knockdown of c-Jun', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2013, 'Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2012, 'OUTCOMES OF ETHNIC MINORITY GROUPS WITH NODE-POSITIVE, NON-METASTATIC BREAST CANCER IN A TERTIARY REFERRAL CENTRE IN SYDNEY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 100 - 100, presented at
, 2012, 'Phase III, randomised, double-blind, placebo-controlled study of Modafinil for fatigue in patients treated with Docetaxel-based chemotherapy', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 26 - 26, presented at
, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at
, 2012, 'Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2012, 'Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, IL, presented at
, 2012, 'Association of Radiographic Progression-Free Survival (Rpfs) adapted from Prostate Cancer Working Group 2 (Pcwg2) Consensus Criteria (Apcwg2) with Overall Survival (Os) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Results from Cou-Aa-302', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 23 294-295; 9 SEP 2012, presented at
, 2012, 'hENT1 expression in human urothelium; evaluating hENT1 prognostic potential for intravesical Gemcitabine treatment outcome in patients with superficial urothelial carcinoma', in BJU International, Urological Society of Australia and New Zealand, Darwin, pp. 109 40-40; 4 SI APR 2012, presented at
, 2012, 'Outcomes of ethnic minority groups with node-positive, non-metastatic breast cancer in a tertiary referral centre in Sydney', in Annals of Oncology, Oxford Univ Press, Oxford, England, pp. 23 100-100; 9 SEP 2012, presented at
, 2012, 'Tumour:node ratio in node-positive, non-metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. 8 37-37; 2 SI AUG 2012, presented at
, 2011, 'Increased expression of EGFR in squamous cell carcinoma in recessive dystrophic epidermolysis bullosa and response to Cetuximab', in Australasian Journal of Dermatology, New South Wales : Wiley-Blackwell, Australia, pp. 32 - 32, presented at
, 2010, 'A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) +/- CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, ITALY, Milan, pp. 137 - 137, presented at
, 2010, 'Fatigue after adjuvant therapy for breast cancer influences health care utilisation and perceived needs', in Grunberg SM (ed.), Journal of Clinical Oncology, American Society of Clinical Oncology, Virginia USA, pp. 647s, presented at
, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at
, 2009, 'CRP predicts tolerance of treatment and overall survival with weekly carboplatin-paclitaxel and concomitant irradiation for locally advanced non-small cell lung cancer', in Journal of Thoracic Oncology, Lippincott Williams & Wilkins, USA, pp. S864 - S865, presented at
, 2009, 'Cytidine Deaminase c.79A > C Polymorphism Affected Optimal Dose Delivery of Gemcitabine', in Drug Metabolism Reviews, Marcel Dekker Inc, New York, NY, USA, pp. 231 - 232, presented at
, 2009, 'Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies', in Medical Oncology, Humana Press Inc, Totowa, NJ, USA, presented at
, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at
, 2008, 'A study of rare presentations of metastatic melanoma', in Australasian Journal of Dermatology, New South Wales : Wiley-Blackwell, Australia, pp. A75 - A76, presented at
, 2007, 'Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, 'Lessons learnt in evaluating the target of drug action in a phase 1 trial of oral albendazole –a benzimidazole carbamate anti-helminthic- in patients with cancer refractory to conventional treatments.', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, pp. A79 - A79, presented at
Conference Posters
, 2018, 'Is serum CA15-3 useful for assessing disease progression during systemic therapy in patients with metastatic breast cancer (MBC)?', Vol. 14, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Presentations
, 2015, 'Patterns of care and outcomes among sarcomatoid renal cell carcinoma patients in South Western Sydney', Vol. 11, pp. 180 - 180, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800331&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Conference Abstracts
, 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1096 - S1096, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1320
, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105
, 2022, 'A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 2641 - 2641, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2641
, 2022, 'Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS2671 - TPS2671, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps2671
, 2019, 'AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2604
, 2018, 'Retrospective analysis of clinical characteristics and outcomes for patients enrolled in oncology phase 0 and phase 1 clinical trials at Liverpool Cancer Therapy Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 168 - 169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Retrospective Analysis of Clinical Characteristics and Outcomes for Patients Enrolled on Oncology Phase I Clinical Trials at Liverpool Hospital Cancer Therapy Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 117 - 117, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'Adjuvant chemotherapy for stage III colorectal cancer in the elderly', in Annals of Oncology, Vol. 27, pp. vi182, http://dx.doi.org/10.1093/annonc/mdw370.101
, 2016, 'Early marker of DNA damage response, atm, as a predictor of clinical outcome following radiotherapy in rectal cancer patients.', in Pathology, England, Vol. 48 Suppl 1, pp. S153, England, http://dx.doi.org/10.1016/j.pathol.2015.12.417
, 2015, 'Circulating Tumor Cells in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, Vol. 93, pp. E522 - E523, presented at 57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), TX, San Antonio, 18 October 2015 - 21 October 2015, http://dx.doi.org/10.1016/j.ijrobp.2015.07.1883
, 2015, 'Psychological parameters and circulating tumor cells in locally advanced rectal cancer', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, Vol. 11, pp. 57 - 57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Final analysis of the randomised, phase 3, COU-AA-302 study of abiraterone acetate (AA) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC)', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Adelaide, Vol. 115, pp. 21 - 22, presented at 68th Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Adelaide, 11 April 2015 - 14 April 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351395100042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Final analysis COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel(D) and abiraterone (A) and/or enzalutamide (E)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, Vol. 33, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.141
, 2015, 'Presence of circulating tumour cells and correlation with inflammatory markers in non-metastatic rectal cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, Vol. 51, pp. S391 - S391, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31092-9
, 2015, 'Quality of life and circulating tumour cells in patients treated with neoadjuvant chemoradiation for rectal cancer - is there a link?', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, Vol. 51, pp. S224 - S224, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)30648-7
Preprints
, 2023, Circulating Tumour Cell Associated MicroRNA Profiles Change during Chemoradiation and are Predictive of Response in Locally Advanced Rectal Cancer, , http://dx.doi.org/10.20944/preprints202306.1821.v1
, 2020, Epithelial-to-Mesenchymal Transition and its Association with PD-L1 and CD8 T cells in Thyroid Cancer, , http://dx.doi.org/10.21203/rs.3.rs-34509/v1
, 2020, MiRNA-10b marks aggressive squamous cell carcinomas, and confers a cancer stem cell-like phenotype, , http://dx.doi.org/10.1101/2020.02.05.934109
Filter by type
https://orcid.org/0000-0002-7380-1170